Source comparison
IGF-1 LR3 vs Ipamorelin: Mechanism Comparison
Primary Mechanism Direct IGF-1 receptor agonist; bypasses GH pathway entirely GHSR1a agonist; stimulates endogenous GH release from pituitary IGF-1 LR3 produces immediate tissue effects; Ipamorelin requires functional pituitary and hepatic IGF-1 synthesis Half
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Direct IGF-1 receptor agonist; bypasses GH pathway entirely
- GHSR1a agonist; stimulates endogenous GH release from pituitary
- IGF-1 LR3 produces immediate tissue effects; Ipamorelin requires functional pituitary and hepatic IGF-1 synthesis
- Half-Life
- 20–30 hours (extended via reduced IGFBP binding)
- 2 hours (GH pulse lasts 3–4 hours post-dose)
- IGF-1 LR3 allows once-daily dosing; Ipamorelin requires 2–3 daily administrations
- Dosing Frequency
- Once daily (stable plasma levels)
- 2–3 times daily (mimics natural GH pulses)
- Ipamorelin's pulsatile pattern better replicates physiology; IGF-1 LR3 offers dosing convenience
- Systemic vs Local
- Can be administered locally for site-specific effects
- Systemic only. GH release affects whole organism
- IGF-1 LR3 enables targeted tissue studies; Ipamorelin produces whole-body metabolic changes
- Dependency on GH
- GH-independent (works in hypophysectomized models)
- GH-dependent (requires functional pituitary)
- IGF-1 LR3 suited for GH-deficient or pituitary-compromised models
- Regulatory Cascade
- None. Direct tissue signaling
- Triggers full GH-IGF-1 axis with downstream effects (lipolysis, gluconeogenesis, immune modulation)
- Ipamorelin produces broader physiological effects; IGF-1 LR3 isolates anabolic signaling